EA200501070A1 - Поливалентная вакцинная композиция - Google Patents

Поливалентная вакцинная композиция

Info

Publication number
EA200501070A1
EA200501070A1 EA200501070A EA200501070A EA200501070A1 EA 200501070 A1 EA200501070 A1 EA 200501070A1 EA 200501070 A EA200501070 A EA 200501070A EA 200501070 A EA200501070 A EA 200501070A EA 200501070 A1 EA200501070 A1 EA 200501070A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccine composition
conjugate
influenzae
composition containing
capsular polysaccharide
Prior art date
Application number
EA200501070A
Other languages
English (en)
Other versions
EA011480B1 (ru
Inventor
Доминик Бутрио
Карин Капио
Пьер Мишель Десмон
Доминик Лемуан
Жан Пулман
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27255788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200501070(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0015999.6A external-priority patent/GB0015999D0/en
Priority claimed from GBGB0108364.1A external-priority patent/GB0108364D0/en
Priority claimed from GB0108363A external-priority patent/GB0108363D0/en
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA200501070A1 publication Critical patent/EA200501070A1/ru
Publication of EA011480B1 publication Critical patent/EA011480B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Описана поливалентная вакцинная композиция, содержащая конъюгат капсульного полисахарида H. influenzae b, не адсорбированный на адъювантной соли алюминия, и два или более чем два дополнительных бактериальных полисахарида. Также описана поливалентная вакцинная композиция, содержащая цельноклеточный коклюшный компонент, столбнячный анатоксин, дифтерийный анатоксин, поверхностный антиген гепатита B, конъюгат капсульного полисахарида H. influenzae b и конъюгат капсульного полисахарида N. meningitidis типа A или C (или обоих). Кроме того, описана поливалентная вакцинная композиция, содержащая цельноклеточный коклюшный компонент, столбнячный анатоксин, дифтерийный анатоксин и низкую дозу конъюгата капсульного полисахарида H. influenzae b.Отчет о международном поиске был опубликован 2002.06.13.
EA200501070A 2000-06-29 2001-06-27 Поливалентная вакцинная композиция EA011480B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0015999.6A GB0015999D0 (en) 2000-06-29 2000-06-29 Novel compounds
GBGB0108364.1A GB0108364D0 (en) 2001-04-03 2001-04-03 Vaccine composition
GB0108363A GB0108363D0 (en) 2001-04-03 2001-04-03 Vaccine composition

Publications (2)

Publication Number Publication Date
EA200501070A1 true EA200501070A1 (ru) 2006-02-24
EA011480B1 EA011480B1 (ru) 2009-04-28

Family

ID=27255788

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200501070A EA011480B1 (ru) 2000-06-29 2001-06-27 Поливалентная вакцинная композиция
EA200201240A EA006313B1 (ru) 2000-06-29 2001-06-27 Поливалентные иммуногенные композиции и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200201240A EA006313B1 (ru) 2000-06-29 2001-06-27 Поливалентные иммуногенные композиции и способы их применения

Country Status (35)

Country Link
US (2) US20030180316A1 (ru)
EP (4) EP2279748A1 (ru)
JP (2) JP4870895B2 (ru)
KR (3) KR20070091698A (ru)
CN (2) CN1449293B (ru)
AP (1) AP1695A (ru)
AT (1) ATE534402T1 (ru)
AU (2) AU2001281895C1 (ru)
BG (2) BG66238B1 (ru)
BR (2) BR122012003821B8 (ru)
CA (2) CA2783274C (ru)
CY (2) CY1112280T1 (ru)
CZ (1) CZ20024224A3 (ru)
DK (2) DK1946769T3 (ru)
DZ (1) DZ3399A1 (ru)
EA (2) EA011480B1 (ru)
EG (1) EG24742A (ru)
ES (2) ES2375704T5 (ru)
HK (1) HK1055244A1 (ru)
HU (3) HU227893B1 (ru)
IL (2) IL153506A0 (ru)
MA (1) MA25824A1 (ru)
MX (1) MXPA03000198A (ru)
MY (1) MY133981A (ru)
NO (1) NO332495B1 (ru)
NZ (1) NZ523319A (ru)
OA (1) OA12302A (ru)
PE (1) PE20020126A1 (ru)
PL (2) PL210015B1 (ru)
PT (2) PT1946769E (ru)
SI (2) SI1946769T1 (ru)
SK (1) SK288007B6 (ru)
UA (2) UA85853C2 (ru)
UY (1) UY26801A1 (ru)
WO (1) WO2002000249A2 (ru)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4540795B2 (ja) * 2000-03-10 2010-09-08 一般財団法人阪大微生物病研究会 生ワクチンの細胞性免疫活性を不活化ワクチンにも起こさせる方法、及びこれより得られる混合ワクチン
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
HU227893B1 (en) 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
DK2332581T3 (en) 2001-01-23 2015-10-05 Sanofi Pasteur Inc Tri- or tetravalent meningococcal polysaccharide-crm197 conjugate vaccine
AU2007200116A1 (en) * 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
CA2448066A1 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
ATE513560T1 (de) * 2002-05-14 2011-07-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
EP1556477B1 (en) * 2002-11-01 2017-08-09 GlaxoSmithKline Biologicals s.a. Drying process
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
JP2006516609A (ja) * 2003-01-30 2006-07-06 カイロン ソチエタ ア レスポンサビリタ リミタータ 粘膜髄膜炎菌性ワクチン
WO2005004909A2 (en) 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2530434A1 (en) * 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
CA2885040C (en) 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23404A1 (es) * 2003-11-19 2009-08-04 Ct Ingenieria Genetica Biotech Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
PL1740217T3 (pl) 2004-04-30 2012-03-30 Novartis Ag Szczepienie koniugatem meningokokowym
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1871411A4 (en) 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic EXPRESSION OF HEPATITIS B VIRUS SURFACE ANTIGEN FOR VACCINE MANUFACTURE
PE20110072A1 (es) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
CN1709505B (zh) * 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
US8007807B2 (en) 2005-09-01 2011-08-30 Novartis Vaccines And Diagnostics Gmbh Multiple vaccination including serogroup C meningococcus
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2816182C (en) 2005-12-22 2018-02-20 Glaxosmithkline Biologicals S.A. Pneumococcal polysaccharide conjugate vaccine
AU2006327023A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
ZA200805602B (en) * 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
EP2004225B1 (en) 2006-03-22 2012-04-25 Novartis AG Regimens for immunisation with meningococcal conjugates
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP1872791A1 (en) 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
EP2066344B2 (en) * 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Inactivated Poliovirus combination vaccine
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
BRPI0811979A2 (pt) 2007-06-04 2014-10-21 Novartis Ag Formulação para vacinas de meningite
KR101579947B1 (ko) 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
MX2010012999A (es) * 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
ES2614807T3 (es) * 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
PL2651436T3 (pl) * 2010-12-14 2016-10-31 Kompozycja antygenów mykobakteryjnych
CN103442730B (zh) 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
JP6042455B2 (ja) * 2012-01-30 2016-12-14 セラム インスティチュート オブ インディア プライベイト リミテッド 免疫原性組成物の調製方法
WO2013132043A1 (en) * 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
RU2015111987A (ru) 2012-10-12 2016-12-10 Глаксосмитклайн Байолоджикалс Са Несшитые бесклеточные коклюшные антигены для применения в комбинированных вакцинах
EA201590490A1 (ru) * 2012-10-17 2015-10-30 Глаксосмитклайн Байолоджикалс С.А. ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ОДИН ИЛИ БОЛЕЕ КОНЪЮГАТОВ КАПСУЛЬНЫХ САХАРИДОВ STREPTOCOCCUS PNEUMONIAE И БЕЛКОВЫЙ КОМПОНЕНТ, ВКЛЮЧАЮЩИЙ БЕЛОК Е И/ИЛИ PilA ИЗ HAEMOPHILIUS INFLUENZAE
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
MY172181A (en) 2013-03-08 2019-11-15 Janssen Vaccines & Prevention Bv Acellular pertussis vaccine
MX2016000099A (es) * 2013-07-07 2016-07-07 Max Planck Ges Zur Förderung Der Wissenschaften E V Vacunas sinteticas contra streptococcus pneumoniae tipo 1.
EP3492097A1 (en) 2013-08-05 2019-06-05 GlaxoSmithKline Biologicals S.A. Combination immunogenic compositions
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
US10888611B2 (en) * 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112019001971A2 (pt) 2016-08-05 2019-05-07 Sanofi Pasteur, Inc. composição conjugada de polissacarídeo-proteína pneumocócica multivalente
WO2018027123A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017321863A1 (en) 2016-09-02 2019-04-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
MA51049A (fr) 2017-12-06 2020-10-14 Merck Sharp & Dohme Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
CA3087572A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2020008198A (es) 2018-02-05 2020-09-22 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente neumococica.
CA3096358A1 (en) 2018-04-18 2019-10-24 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharide and immunogenic conjugate thereof
EP3788143B1 (en) * 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
KR20200005458A (ko) 2018-07-06 2020-01-15 주식회사 유바이오로직스 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물
MX2021005500A (es) * 2018-11-10 2021-09-08 Bharat Biotech Int Ltd Composiciones inmunogenicas de glicoconjugados multivalentes.
BR112021011961A8 (pt) 2018-12-19 2023-02-07 Merck Sharp & Dohme Composições compreendendo conjugados de polissacarídeo-proteína de streptococcus pneumoniae e métodos de uso dos mesmos
EP3972637A4 (en) 2019-05-20 2023-06-21 Soligenix, Inc. COMPOSITIONS AND METHODS OF MANUFACTURE OF TRIVAL FILOVIRUS VACCINES
CN111821432B (zh) * 2020-08-05 2022-10-18 北京智飞绿竹生物制药有限公司 一种多价肺炎球菌结合疫苗

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) * 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
JPS6061288A (ja) * 1983-09-13 1985-04-09 Fuji Photo Film Co Ltd 感熱記録材料
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8516442D0 (en) 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
JP3506431B2 (ja) 1992-05-06 2004-03-15 プレジデント アンド フェローズ オブ ハーバード カレッジ ジフテリア毒素受容体結合領域
SK280702B6 (sk) 1992-05-23 2000-06-12 Smithkline Beecham Biologicals S. A. Kombinovaný očkovací prostriedok obsahujúci povrch
DE69327534T2 (de) 1992-06-18 2000-06-08 Harvard College Impfstoffe gegen diphtherietoxin
UA40597C2 (ru) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинная композиция, способ лечения млекопитающих, больных или восприимчивых к инфекции, способ лечения млекопитающих, больных на рак, способ получения вакцинной композиции, композиция адъювантов
DE69323264T4 (de) * 1992-10-27 1999-10-14 American Cyanamid Co Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
PT833662E (pt) * 1995-06-23 2001-09-28 Smithkline Beecham Biolog Uma composicao vacinal compreendendo um antigenio polissacaridico conjugado adsorvido a fosfato de aluminio
US5997881A (en) 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
WO1998033923A1 (en) 1997-01-30 1998-08-06 Imperial College Of Science, Technology & Medicine MUTANT msbB or htrB GENES
BR9714980A (pt) * 1997-09-15 2001-11-06 Pasteur Merieux Msd Vacinas multivalentes
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
HU227893B1 (en) 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
PE20110072A1 (es) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2816182C (en) * 2005-12-22 2018-02-20 Glaxosmithkline Biologicals S.A. Pneumococcal polysaccharide conjugate vaccine
AU2006327023A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
JP4858611B2 (ja) * 2007-03-14 2012-01-18 コニカミノルタビジネステクノロジーズ株式会社 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
JP2010525035A (ja) * 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
BRPI0811979A2 (pt) * 2007-06-04 2014-10-21 Novartis Ag Formulação para vacinas de meningite
KR101579947B1 (ko) * 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신

Also Published As

Publication number Publication date
CZ20024224A3 (cs) 2003-05-14
PT1946769E (pt) 2012-06-27
HUP0301413A3 (en) 2010-01-28
SI1296715T1 (sl) 2012-03-30
WO2002000249A3 (en) 2002-06-13
SK18432002A3 (sk) 2003-08-05
AU2001281895C1 (en) 2005-10-27
IL153506A (en) 2009-06-15
EA006313B1 (ru) 2005-10-27
PL210015B1 (pl) 2011-11-30
US9233151B2 (en) 2016-01-12
HU227613B1 (en) 2011-09-28
CY1112280T1 (el) 2015-12-09
ES2385100T3 (es) 2012-07-18
WO2002000249A2 (en) 2002-01-03
CA2412497C (en) 2012-10-02
CY1112915T1 (el) 2016-04-13
PL360265A1 (en) 2004-09-06
UY26801A1 (es) 2002-01-31
DK1296715T4 (en) 2016-03-07
HUP0301413A1 (hu) 2003-08-28
SI1296715T2 (sl) 2016-03-31
BR0112057A (pt) 2003-06-17
PT1296715E (pt) 2012-01-19
NZ523319A (en) 2006-01-27
EP1296715B2 (en) 2015-12-23
BG66238B1 (bg) 2012-08-31
HK1055244A1 (en) 2004-01-02
AU2001281895B2 (en) 2005-04-28
CA2412497A1 (en) 2002-01-03
OA12302A (en) 2003-10-24
BR122012003821B1 (pt) 2020-09-01
CN101708333A (zh) 2010-05-19
EG24742A (en) 2010-07-14
JP4870895B2 (ja) 2012-02-08
KR100898845B1 (ko) 2009-05-21
BRPI0112057B8 (pt) 2021-05-25
EP1946769B1 (en) 2012-05-30
JP2010163453A (ja) 2010-07-29
CN1449293A (zh) 2003-10-15
UA76952C2 (ru) 2006-10-16
EA011480B1 (ru) 2009-04-28
EP2277541A1 (en) 2011-01-26
SI1946769T1 (sl) 2012-07-31
KR100837917B1 (ko) 2008-06-13
ATE534402T1 (de) 2011-12-15
JP5346308B2 (ja) 2013-11-20
CN1449293B (zh) 2012-08-22
CA2783274C (en) 2018-08-07
BG110518A (bg) 2010-04-30
UA85853C2 (ru) 2009-03-10
BG66249B1 (en) 2012-09-28
JP2004501873A (ja) 2004-01-22
EP1296715B1 (en) 2011-11-23
KR20070091698A (ko) 2007-09-11
AU8189501A (en) 2002-01-08
PE20020126A1 (es) 2002-04-27
NO20026175D0 (no) 2002-12-20
ES2375704T3 (es) 2012-03-05
SK288007B6 (sk) 2012-10-02
MXPA03000198A (es) 2004-09-13
HU227893B1 (en) 2012-05-29
EP1946769A2 (en) 2008-07-23
EP1946769A3 (en) 2008-07-30
HU1000593D0 (en) 2010-12-28
NO20026175L (no) 2003-02-26
MY133981A (en) 2007-11-30
CA2783274A1 (en) 2002-01-03
AP2002002700A0 (en) 2002-12-31
HU1000594D0 (en) 2010-12-28
CN101708333B (zh) 2014-03-26
EP1296715A2 (en) 2003-04-02
BRPI0112057B1 (pt) 2016-10-04
EA200201240A1 (ru) 2003-06-26
EP2279748A1 (en) 2011-02-02
BR122012003821B8 (pt) 2021-05-25
BG107422A (bg) 2003-09-30
DK1296715T3 (da) 2012-02-13
KR20080052700A (ko) 2008-06-11
AP1695A (en) 2006-12-17
IL153506A0 (en) 2003-07-06
NO332495B1 (no) 2012-10-01
DK1946769T3 (da) 2012-07-16
US20030180316A1 (en) 2003-09-25
MA25824A1 (fr) 2003-07-01
DZ3399A1 (fr) 2002-01-03
ES2375704T5 (es) 2016-03-03
US20120207780A1 (en) 2012-08-16
KR20030024714A (ko) 2003-03-26
PL393584A1 (pl) 2011-05-23
HU228384B1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
EA200501070A1 (ru) Поливалентная вакцинная композиция
RU2012116119A (ru) Множественная вакцинация, включающая менингококки серогруппы с
DK0764029T4 (da) Proteinadjuvanser
ATE480257T1 (de) Kombinationsvakzine mit niedriger dosis eines hib-konjugats
LU91924I2 (fr) Composition vaccinale comprenant le polysaccharidecapsulaire et Haemophilus influenzae type b coupl é à l'anatoxine tétanique, l'antigène diphtérique,l'antigène tétanique, des antigènes de la polio, des antigènes de la coqueluche et du phosphate d'aluminium
RU2009149359A (ru) Состав вакцин против менингита
KR920002790A (ko) 보르데텔라 퍼투스시스에 의해 발병되는 질병을 예방하는데 유효한 백신 및 비백일해 백신 성분과 조합된 상기 백신으로 구성되는 다가성 백신
RU2009108660A (ru) Вакцины на основе солюбилизированных и комбинированных капсулярных полисахаридов
JP2004501873A5 (ru)
AR014762A1 (es) PROCEDIMIENTO PARA REDUCIR LA INTERFERENCIA DE COMPONENTES POLISACARIDOS CAPSULARES, DE VACUNAS CONJUGADAS DE HAEMOPHILUS INFLUENZAE B (Hib) EN VACUNASDE COMBINACION, VACUNAS DE COMBINACION OBTENIDAS CON DICHO PROCEDIMIENTO DE VACUNACION CONTRA LA DIFTERIA, TETANO, PERTUSSIS Y HAEMOPHILUS INFLUENZAE
BRPI9710460B8 (pt) composição imunogênica multi-valente e composição de vacina
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
UA27754C2 (ru) Комбинированная педиатрическая вакцина, способ одновременной комбинированной вакцинации

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MK4A Patent expired

Designated state(s): BY KZ RU